Cellular immunotherapy is a process in which patient’s disease-fighting T-cells are extracted and engineered to identify the type of cancer. A special type of virus is used to insert DNA into immune cells which helps T-cells through receptor to recognize and kill cancer cells. CAR-T cells are hybrid which is infused to kill cancer cells.
Researchers from the University of North Carolina Lineberger came up with results of their investigational cellular immunotherapy. In this therapy, the patient’s own immune cells recognized and fought against Hodgkin and Non-Hodgkin lymphoma cells expressing the CD30 protein marker. Positive results were obtained by the treatment in phase Ib/II trial. This was a safe treatment which showed an excellent response in those patients who were earlier being treated by chemotherapy regimen. Only fewer patients with bad disease showed no response to immunotherapy.
Researchers studied 24 patients with Hodgkin Lymphoma. Many of them had given prior treatments, including the one by brentuximab vedotin. Lymph-depletion is a method in which patients are treated by chemotherapy prior to CAR-T therapy. Fluderabine and Bendamustine were used in chemotherapy. Among 14 patient, 10 showed complete response with a median progression Free survival of 369 days. 2 patients were in complete response before receiving chemotherapy regimen. 8 patients received bendamustine alone in treatment and among them, 3 came up with complete response.
According to Barbara Savoldo, the most important achievement was the identification of lymphodepletion regimen that can create a difference for patients with different toxicities while being used with specific CAR-T cells. Researchers are still busy to come up with better results. Their aim is to recruit CAR-T cells at tumor sites to achieve better results and more effectiveness.